What is Labcorp Holdings's drug development — operating income (loss)?

Labcorp Holdings (LH) reported drug development — operating income (loss) of $120.90M in Q3 2024.

How has Labcorp Holdings's drug development — operating income (loss) changed year-over-year?

Labcorp Holdings's drug development — operating income (loss) increased by 10.9% year-over-year, from $109.00M to $120.90M.

What is the long-term trend for Labcorp Holdings's drug development — operating income (loss)?

Over 2 years (2021 to 2023), Labcorp Holdings's drug development — operating income (loss) has grown at a -11.1% compound annual growth rate (CAGR), from $501.00M to $396.30M.

What does drug development — operating income (loss) mean?

The profit or loss generated by the drug development business segment after operating expenses.

Discontinued — last reported Q3 '24

Business Segments · Operating Income (Loss)

Drug Development — Operating Income (Loss)

Labcorp Holdings Drug Development — Operating Income (Loss) increased by 12.6% to $120.90M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 10.9%, from $109.00M to $120.90M. Over 2 years (FY 2021 to FY 2023), Drug Development — Operating Income (Loss) shows a downward trend with a -11.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment

CategoryProfitability

SignalHigher is better

VolatilityModerate

First reportedQ1 2014

Last reportedQ3 2024

Rolls up toOperating Income

How to read this metric

An increase indicates improved operational efficiency or higher margins on research contracts, while a decrease suggests rising costs or pricing pressure.

Detailed definition

This metric represents the profitability of the drug development segment after deducting operating expenses such as labo...

Peer comparison

Comparable to segment operating margin or segment EBIT for peer companies in the clinical research and laboratory services industry.

Metric ID: lh_segment_drug_development_operating_income_loss

Historical Data

14 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24
Value	$147.30M	$141.60M	$55.70M	$168.60M	$93.00M	$105.00M	$95.20M	$73.60M	$104.60M	$109.00M	$109.10M	$99.90M	$107.40M	$120.90M
QoQ Change	—	-3.9%	-60.7%	+202.7%	-44.8%	+12.9%	-9.3%	-22.7%	+42.1%	+4.2%	+0.1%	-8.4%	+7.5%	+12.6%
YoY Change	—	—	—	—	-36.9%	-25.8%	+70.9%	-56.3%	+12.5%	+3.8%	+14.6%	+35.7%	+2.7%	+10.9%

Range$55.70M – $168.60M

CAGR-5.9%

Avg YoY Growth+3.2%

Median YoY Growth+7.4%

Current Streak2 quarters growth

Similar Metrics at Other Companies

Agilent TechnologiesA View metric

Quest DiagnosticsDGX View metric

HPHPQ View metric

Quest DiagnosticsDGX View metric

IlluminaILMN View metric

Frequently Asked Questions

What is Labcorp Holdings's drug development — operating income (loss)?: Labcorp Holdings (LH) reported drug development — operating income (loss) of $120.90M in Q3 2024.
How has Labcorp Holdings's drug development — operating income (loss) changed year-over-year?: Labcorp Holdings's drug development — operating income (loss) increased by 10.9% year-over-year, from $109.00M to $120.90M.
What is the long-term trend for Labcorp Holdings's drug development — operating income (loss)?: Over 2 years (2021 to 2023), Labcorp Holdings's drug development — operating income (loss) has grown at a -11.1% compound annual growth rate (CAGR), from $501.00M to $396.30M.
What does drug development — operating income (loss) mean?: The profit or loss generated by the drug development business segment after operating expenses.